CoChat

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy

Open access
Bertran-Alamillo, Jordi, Cattan, Valérie, Schoumacher, Marie, Codony-Servat, Jordi, Giménez-Capitán, Ana, Cantero, Frédérique, Burbridge, Mike, Rodríguez, Sonia, Teixidó, Cristina, Roman, Ruth, Castellví, Josep, García-Román, Silvia, Codony-Servat, Carles, Viteri, Santiago, Cardona, Andrés-Felipe, Karachaliou, Niki, Rosell, Rafael, Molina-Vila, Miguel-Angel · 2019 · Nature Communications
Cited by 138

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Non-small cell lung cancer (NSCLC) tumors harboring mutations in EGFR ultimately relapse to therapy with EGFR tyrosine kinase inhibitors (EGFR TKIs). Here, we show that resistant cells without the p.T790M or other acquired mutations are sensitive to the Aurora B (AURKB) inhibitors barasertib and S49076. Phospho-histone H3 (pH3), a major product of AURKB, is increased in most resistant cells and treatment with AURKB inhibitors reduces the levels of pH3, triggering G1/S arrest and polyploidy. Senescence is subsequently induced in cells with acquired mutations while, in their absence, polyploidy is followed by cell death. Finally, in NSCLC patients, pH3 levels are increased after progression on EGFR TKIs and high pH3 baseline correlates with shorter survival. Our results reveal that AURKB activation is associated with acquired resistance to EGFR TKIs, and that AURKB constitutes a potential target in NSCLC progressing to anti-EGFR therapy and not carrying resistance mutations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-09734-5

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 138

Metadata

Authors
Bertran-Alamillo, J., Cattan, V., Schoumacher, M., Codony-Servat, J., Giménez-Capitán, A., Cantero, F., Burbridge, M., Rodríguez, S., Teixidó, C., Roman, R., Castellví, J., García-Román, S., Codony-Servat, C., Viteri, S., Cardona, A.-F., Karachaliou, N., Rosell, R., & Molina-Vila, M.-A.
Venue
Nature Communications
Published
2019-04-18
Volume
10
Issue
1
Pages
1812-1812
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2937830908
Cited by
138
References
13
FWCI
14.50
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy. https://app.cochat.ai/papers/10.1038/s41467-019-09734-5
The paper
Bertran-Alamillo, J., Cattan, V., Schoumacher, M., Codony-Servat, J., Giménez-Capitán, A., Cantero, F., Burbridge, M., Rodríguez, S., Teixidó, C., Roman, R., Castellví, J., García-Román, S., Codony-Servat, C., Viteri, S., Cardona, A.-F., Karachaliou, N., Rosell, R., & Molina-Vila, M.-A. (2019). AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy. Nature Communications. https://doi.org/10.1038/s41467-019-09734-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.